Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 20/20 | 0.73 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9582052 | 1.00 | DRD4 (0.73) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL9582407 | 1.00 | DRD4 (0.73) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL23581719 | 0.87 | DRD4 (0.57) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL23581705 | 0.87 | DRD4 (0.57) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL23581706 | 0.87 | DRD4 (0.57) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL1927637 | 0.86 | DRD4 (0.63) | DRD4DRD2 | |
| SCHEMBL9581802 | 0.86 | DRD4 (0.66) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL3487336 | 0.84 | DRD4 (0.64) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL13734323 | 0.84 | DRD4 (0.85) | DRD4 | |
| SCHEMBL13734321 | 0.84 | DRD4 (0.85) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380878-B1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO CO LTD (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2380878-B1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO CO LTD (JP) | 2013-08-14 | — | — | EP | disclosed |
| CN-102325754-A | Cyclic compound having hetero atom | DAIICHI SANKYO CO LTD | 2012-01-18 | — | — | CN | disclosed |
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| EP-2380878-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010082563-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | 第一三共株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
| US-5191079-A | Chemical intermediates for bactericides | KANEBO, LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
| US-5166203-A | QUINOLINECARBOXYLIC ACID DERIVATIVES, ANTIBACTERIAL AGENT CONTAINING THE SAME | KANEBO, LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| EP-0472826-A2 | Novel quinolinecarboxylic acid derivatives, use thereof, antibacterial agent containing the same, process for preparing said compounds and intermediate compound | KANEBO LTD. (JP) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269746-A1 | CYCLIC COMPOUND HAVING HETERO ATOM | BMP2, BMP4, BMP1 | DRD4 4166/4885DRD2 4317/4885DRD3 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.